Large cell neuroendocrine carcinoma transformation: A novel acquired drug resistance mechanism in colorectal adenocarcinoma

Cancer Innovation Pub Date : 2023-03-20 DOI:10.1002/cai2.57
Feng Du, Ying Han, Xiao Hu, Yanjie Xiao, Youwu Shi, Jing Sun, Zhiwei Sun, Ying Yang, Jing Yu, Xiaodong Zhang, Jun Jia
{"title":"Large cell neuroendocrine carcinoma transformation: A novel acquired drug resistance mechanism in colorectal adenocarcinoma","authors":"Feng Du,&nbsp;Ying Han,&nbsp;Xiao Hu,&nbsp;Yanjie Xiao,&nbsp;Youwu Shi,&nbsp;Jing Sun,&nbsp;Zhiwei Sun,&nbsp;Ying Yang,&nbsp;Jing Yu,&nbsp;Xiaodong Zhang,&nbsp;Jun Jia","doi":"10.1002/cai2.57","DOIUrl":null,"url":null,"abstract":"<p>Acquired resistance is a major problem limiting the clinical efficacy of treatments for metastatic colorectal cancer (mCRC). Histological transformation is an important mechanism underlying the acquired resistance of non-small cell lung cancer and prostate cancer to targeted therapy. However, no report has examined the role of histological transformation in mCRC. Here, we report the first case of histologically transformed large cell neuroendocrine carcinoma from primary colon adenocarcinoma during antiangiogenesis and anti-PD-1 combination therapy. The histologic conversion was confirmed by the observation that the transformed large cell neuroendocrine carcinoma lesion retained the original mutational signature found in the primary tumor. Sequential tumor biopsy and dynamic changes in tumor markers demonstrated the transformed process. The histological transformation not only resulted in discordant responses to the same treatment but also significantly shortened overall survival. This case calls for more attention to histological transformation in mCRC. Tumor rebiopsy upon disease progression and monitoring dynamic changes in tumor markers would help to identify such cases.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.57","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acquired resistance is a major problem limiting the clinical efficacy of treatments for metastatic colorectal cancer (mCRC). Histological transformation is an important mechanism underlying the acquired resistance of non-small cell lung cancer and prostate cancer to targeted therapy. However, no report has examined the role of histological transformation in mCRC. Here, we report the first case of histologically transformed large cell neuroendocrine carcinoma from primary colon adenocarcinoma during antiangiogenesis and anti-PD-1 combination therapy. The histologic conversion was confirmed by the observation that the transformed large cell neuroendocrine carcinoma lesion retained the original mutational signature found in the primary tumor. Sequential tumor biopsy and dynamic changes in tumor markers demonstrated the transformed process. The histological transformation not only resulted in discordant responses to the same treatment but also significantly shortened overall survival. This case calls for more attention to histological transformation in mCRC. Tumor rebiopsy upon disease progression and monitoring dynamic changes in tumor markers would help to identify such cases.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大细胞神经内分泌癌转化:结直肠腺癌新的获得性耐药机制
获得性耐药性是限制转移性癌症(mCRC)治疗临床疗效的主要问题。组织学转化是非小细胞肺癌癌症和癌症对靶向治疗的获得性耐药性的重要机制。然而,还没有研究组织学转化在mCRC中的作用。在这里,我们报道了第一例在抗血管生成和抗PD-1联合治疗期间由原发性结肠癌组织学转化的大细胞神经内分泌癌。通过观察转化的大细胞神经内分泌癌病变保留了原发肿瘤中发现的原始突变特征,证实了组织学转化。连续的肿瘤活检和肿瘤标志物的动态变化证明了这一转变过程。组织学转变不仅导致对相同治疗的不一致反应,而且显著缩短了总生存期。该病例需要更多关注mCRC的组织学转化。对疾病进展进行肿瘤再活检并监测肿瘤标志物的动态变化将有助于识别此类病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
期刊最新文献
Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer Prognostic nomograms for young breast cancer: A retrospective study based on the SEER and METABRIC databases Retinoic acid receptor responder 2 and lipid metabolic reprogramming: A new insight into brain metastasis Leukocyte immunoglobulin-like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1